Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ...

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

IDEAYA Biosciences has secured FDA agreement on its Phase 3 registrational trial design for IDE849, targeting extensive stage small cell lung cancer, aiming for accelerated and full approval with planned trial initiation by end of 2026.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now have a clear regulatory path to start a Phase 3 trial with IDE849 for lung cancer by end 2026. If you work in oncology therapeutics, accelerating FDA engagement could open doors to confirmatory trial design earlier than usual.

◆ Coverage

1 source · 31 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-meetingphase-3-trialcancer-therapeuticsdll3adcregulatory